Trial Profile

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX-629 (Primary)
Indications Lipoid nephrosis; Nephrotic syndrome
Focus Adverse reactions
Sponsors Aldeyra Therapeutics

Most Recent Events

16 Apr 2024 Status changed from recruiting to withdrawn prior to enrolment.
06 Apr 2023 According to an Aldeyra Therapeutics media release, top-line results from Part 1 of the clinical trial are expected in second half 2023.
16 Feb 2023 Status changed from not yet recruiting to recruiting, according to an Aldeyra Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com